BioTNS selected as host of gov't's ultra-precision digital PCR project

BioTNS, a Korean molecular diagnostics company, was selected as the host organization to spearhead a 30 billion won ($19.53 million) government program to set up technical standards for ultra-precision digital Polymerase Chain Reaction (dPCR) diagnostics, according to the company, Friday. With 15 institutions participating, the program is a seven-year initiative to secure global leadership in next-generation molecular diagnostics by establishing technical standards for dPCR. Through the program, the government seeks to overcome the core limitations of legacy molecular testing methods and build a critical infrastructure for ultra-precision medicine based on domestic technologies. Along with BioTNS, the consortium includes six companies, two state-backed research institutes and seven university hospitals. Participating companies include Gencurix, Hanil Scientific, JNP Medi and Omicsyn, while GC Labs will support clinical validation and commercialization. The National NanoFab Center and the Korea Research Institute of Bioscience and Biotechnology will provide technology support. Seven hosp